<?xml version="1.0" encoding="UTF-8"?>
<p>Evidence-based antiemetic guidelines [
 <xref rid="mdx698-B7" ref-type="bibr">7â€“9</xref>] for patients receiving highly emetogenic chemotherapy (HEC) consistently recommend co-administration of a triplet antiemetic regimen of a 5-hydroxytryptamine-3 (5-HT
 <sub>3</sub>) receptor antagonist (RA), a neurokinin-1 (NK
 <sub>1</sub>) RA and a corticosteroid, such as dexamethasone (DEX). The American Society of Clinical Oncology (ASCO) has also recently recommended the addition of olanzapine to this triplet regimen [
 <xref rid="mdx698-B7" ref-type="bibr">7</xref>]. 
</p>
